von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis

doi:10.3748/wjg.v22.i19.4786

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 19

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8489)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

654

WORD

287

HTML

4394

Sum=5335

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1113

Download

2043

Sum=3156

May 21, 2016 (publication date) through Feb 21, 2026

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Letter to the Editor

World J Gastroenterol. May 21, 2016; 22(19): 4786-4788
Published online May 21, 2016. doi: 10.3748/wjg.v22.i19.4786

von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis

Georgios N Kalambokis, Gerasimos Baltayiannis, Dimitrios Christodoulou

Georgios N Kalambokis, 1^st Division of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece

Gerasimos Baltayiannis, Dimitrios Christodoulou, Division of Gastroenterology, Medical School, University of Ioannina, 45110 Ioannina, Greece

Author contributions: Kalambokis GN and Baltayiannis G wrote this letter; Christodoulou D revised the letter.

Conflict-of-interest statement: The authors declare no conflict of interest.

Correspondence to: Georgios N Kalambokis, MD, Assistant Professor of Internal Medicine, 1^st Division of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece. gkalambo@cc.uoi.gr

Telephone: +30-2651-099735 Fax: +30-2651-007883

Received: January 15, 2016
Peer-review started: January 18, 2016
First decision: January 28, 2016
Revised: February 15, 2016
Accepted: March 1, 2016
Article in press: March 1, 2016
Published online: May 21, 2016
Processing time: 123 Days and 7.3 Hours

Abstract

Increased thrombotic potential within the liver sinusoids due to local endothelial production of von Willebrand factor antigen macromolecules could represent an additional therapeutic target of portal hypertension in patients with cirrhosis. In this case, anti-inflammatory and antithrombotic drugs could modulate portal pressure by preventing the formation of intrahepatic platelet-induced microthrombi.

Keywords: von Willebrand factor antigen; Endothelial dysfunction; Treatment; Portal hypertension

Core tip: The purpose of this letter to the Editor is to comment on the potential contribution of increased intrahepatic levels of von Willebrand factor as an additional mechanism that could be related to increased portal pressure in patients with cirrhosis and propose drugs which could decrease portal pressure on the basis of von Willebrand factor’s production or effects.